Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration.

Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. · 2008

Read Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. by Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. (2008) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2253608.txt.

Description

Kirsch and co-workers meta-analysed antidepressant trials in 2008 using the full data submitted to the United States Food and Drug Administration. Published analyses showed only modest drug benefits over placebo, and including unpublished trials shrank them further. The team obtained licensing trial data for four new-generation antidepressants. They tested whether the drug-placebo gap depends on how severe patients' depression was at the start.

The gap grew with initial severity, from virtually nothing at moderate depression to a small difference in very severe cases. It reached conventional clinical significance only at the upper end of the very severe range. The pattern came mainly from placebo response falling in the sickest patients, not from drug response rising. Meta-regression showed improvement in drug groups followed a curved relation with baseline severity.

Catalog record

CREATORKirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT.
YEAR2008
COLLECTIONPAPERS
FORMATTXT
FILE SIZE40 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC2253608

Browse the full library · About the Tower of Babel